Skip to Main Content
Skip Nav Destination

Issues

In This Issue

Diabetes Care December 2015, Vol.39, 1-2. doi:https://doi.org/10.2337/dc16-ti01

Presidential Address

Diabetes Care December 2015, Vol.39, 3-9. doi:https://doi.org/10.2337/dc15-1818

Editor’s Commentary

Diabetes Care December 2015, Vol.39, 10-12. doi:https://doi.org/10.2337/dc15-2315

Considerations in the Management of Gestational Diabetes Mellitus

Diabetes Care December 2015, Vol.39, 13-15. doi:https://doi.org/10.2337/dci15-0030
Diabetes Care December 2015, Vol.39, 16-23. doi:https://doi.org/10.2337/dc15-0540
Diabetes Care July 2015, Vol.39, 24-30. doi:https://doi.org/10.2337/dc15-0511
Diabetes Care July 2015, Vol.39, 31-38. doi:https://doi.org/10.2337/dc15-0572
Diabetes Care July 2015, Vol.39, 39-42. doi:https://doi.org/10.2337/dc15-0515
Diabetes Care November 2015, Vol.39, 43-49. doi:https://doi.org/10.2337/dc15-1642
Diabetes Care June 2015, Vol.39, 50-52. doi:https://doi.org/10.2337/dc15-1001
Diabetes Care October 2015, Vol.39, 53-54. doi:https://doi.org/10.2337/dc15-1887
Diabetes Care October 2015, Vol.39, 55-60. doi:https://doi.org/10.2337/dc15-1421
Diabetes Care November 2015, Vol.39, 61-64. doi:https://doi.org/10.2337/dc15-2027
Diabetes Care April 2015, Vol.39, 65-74. doi:https://doi.org/10.2337/dc15-1254

Clinical Care / Education / Nutrition / Psychosocial Research

Diabetes Care December 2015, Vol.39, 75-81. doi:https://doi.org/10.2337/dc15-0433
Diabetes Care November 2015, Vol.39, 82-91. doi:https://doi.org/10.2337/dc15-1518
John B. Buse; for the IMAGINE 5 Investigators; Helena W. Rodbard; for the IMAGINE 5 Investigators; Carlos Trescoli Serrano; for the IMAGINE 5 Investigators; Junxiang Luo; for the IMAGINE 5 Investigators; Tibor Ivanyi; for the IMAGINE 5 Investigators; Juliana Bue-Valleskey; for the IMAGINE 5 Investigators; Mark L. Hartman; for the IMAGINE 5 Investigators; Michelle A. Carey; for the IMAGINE 5 Investigators; Annette M. Chang; for the IMAGINE 5 Investigators
Diabetes Care November 2015, Vol.39, 92-100. doi:https://doi.org/10.2337/dc15-1531

Epidemiology / Health Services Research

Diabetes Care November 2015, Vol.39, 101-109. doi:https://doi.org/10.2337/dc15-1174
Diabetes Care November 2015, Vol.39, 110-117. doi:https://doi.org/10.2337/dc15-1557

Novel Communications in Diabetes

Diabetes Care October 2015, Vol.39, 118-121. doi:https://doi.org/10.2337/dc15-1027

IDF-ADA Translational Symposium

Diabetes Care December 2015, Vol.39, 122-129. doi:https://doi.org/10.2337/dc15-1206
Diabetes Care December 2015, Vol.39, 130-138. doi:https://doi.org/10.2337/dc15-1240
Tomoya Mita; on behalf of the Collaborators on the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A) Trial; Naoto Katakami; on behalf of the Collaborators on the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A) Trial; Hidenori Yoshii; on behalf of the Collaborators on the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A) Trial; Tomio Onuma; on behalf of the Collaborators on the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A) Trial; Hideaki Kaneto; on behalf of the Collaborators on the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A) Trial; Takeshi Osonoi; on behalf of the Collaborators on the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A) Trial; Toshihiko Shiraiwa; on behalf of the Collaborators on the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A) Trial; Keisuke Kosugi; on behalf of the Collaborators on the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A) Trial; Yutaka Umayahara; on behalf of the Collaborators on the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A) Trial; Tsunehiko Yamamoto; on behalf of the Collaborators on the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A) Trial; Hiroki Yokoyama; on behalf of the Collaborators on the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A) Trial; Nobuichi Kuribayashi; on behalf of the Collaborators on the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A) Trial; Hideaki Jinnouchi; on behalf of the Collaborators on the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A) Trial; Masahiko Gosho; on behalf of the Collaborators on the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A) Trial; Iichiro Shimomura; on behalf of the Collaborators on the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A) Trial; Hirotaka Watada; on behalf of the Collaborators on the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A) Trial
Diabetes Care December 2015, Vol.39, 139-148. doi:https://doi.org/10.2337/dc15-0781
Diabetes Care December 2015, Vol.39, 149-157. doi:https://doi.org/10.2337/dc15-0171
Diabetes Care December 2015, Vol.39, 158-165. doi:https://doi.org/10.2337/dc15-0750
Diabetes Care December 2015, Vol.39, 166-174. doi:https://doi.org/10.2337/dc15-0575

Erratum

Jacques Beltrand; on behalf of the GlidKir Study Group; Caroline Elie; on behalf of the GlidKir Study Group; Kanetee Busiah; on behalf of the GlidKir Study Group; Emmanuel Fournier; on behalf of the GlidKir Study Group; Nathalie Boddaert; on behalf of the GlidKir Study Group; Nadia Bahi-Buisson; on behalf of the GlidKir Study Group; Miriam Vera; on behalf of the GlidKir Study Group; Emmanuel Bui-Quoc; on behalf of the GlidKir Study Group; Isabelle Ingster-Moati; on behalf of the GlidKir Study Group; Marianne Berdugo; on behalf of the GlidKir Study Group; Albane Simon; on behalf of the GlidKir Study Group; Claire Gozalo; on behalf of the GlidKir Study Group; Zoubir Djerada; on behalf of the GlidKir Study Group; Isabelle Flechtner; on behalf of the GlidKir Study Group; Jean-Marc Treluyer; on behalf of the GlidKir Study Group; Raphael Scharfmann; on behalf of the GlidKir Study Group; Helene Cavé; on behalf of the GlidKir Study Group; Laurence Vaivre-Douret; on behalf of the GlidKir Study Group; Michel Polak; on behalf of the GlidKir Study Group
Diabetes Care December 2015, Vol.39, 175. doi:https://doi.org/10.2337/dc16-er01

Issues and Events

Diabetes Care December 2015, Vol.39, 176. doi:https://doi.org/10.2337/dc16-ie01

E-Letters: Observations

Diabetes Care October 2015, Vol.39, e1-e2. doi:https://doi.org/10.2337/dc15-1391
Diabetes Care October 2015, Vol.39, e3. doi:https://doi.org/10.2337/dc15-1797
Diabetes Care October 2015, Vol.39, e4-e5. doi:https://doi.org/10.2337/dc15-1778

E-Letters: Comments and Responses

Diabetes Care December 2015, Vol.39, e11. doi:https://doi.org/10.2337/dci15-0018
Diabetes Care December 2015, Vol.39, e12. doi:https://doi.org/10.2337/dc15-1692
Diabetes Care December 2015, Vol.39, e13-e14. doi:https://doi.org/10.2337/dci15-0017
Diabetes Care December 2015, Vol.39, e15-e16. doi:https://doi.org/10.2337/dc15-1408
Diabetes Care December 2015, Vol.39, e17. doi:https://doi.org/10.2337/dci15-0009
Diabetes Care December 2015, Vol.39, e18. doi:https://doi.org/10.2337/dc15-1956
Diabetes Care December 2015, Vol.39, e19. doi:https://doi.org/10.2337/dci15-0026
Diabetes Care December 2015, Vol.39, e6. doi:https://doi.org/10.2337/dc15-1537
Diabetes Care December 2015, Vol.39, e7. doi:https://doi.org/10.2337/dc15-1914
Diabetes Care December 2015, Vol.39, e8. doi:https://doi.org/10.2337/dc15-2053
Diabetes Care December 2015, Vol.39, e9-e10. doi:https://doi.org/10.2337/dc15-1659
Close Modal

or Create an Account

Close Modal
Close Modal